EryDel is a multi-asset, clinical stage biopharmaceutical company headquartered in Bresso (Milan), Italy dedicated to developing and commercializing novel treatments for rare diseases with high unmet need. In 2018 EryDel received the “Most Innovative StartUp Italia Award” chosen from startups across all industries. EryDel specializes in the delivery of drugs using the patient’s own red blood cells. The lead product candidate, EryDex, is currently in Phase III development for the treatment of Ataxia Telangiectasia (AT), a rare neurological disorder for which no established therapy is currently available. EryDex received Orphan Drug designation for the treatment of AT both from FDA and EMA
Company Details
- Employees
- 19
- Founded
- -
- Address
- Via Antonio Meucci, 3, Bresso,lombardia 20091,italy
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- erydel.com
- Keywords
- red blood cell, biotech, platform, rare disease, ataxia telangiectasia, enzyme replacement, science and technology, orphan drugs.
- HQ
- Bresso, Lombardia
Quince Therapeutics Spa Questions
Quince Therapeutics Spa's website is erydel.com
Quince Therapeutics Spa's LinkedIn profile is https://it.linkedin.com/company/quince-spa
Quince Therapeutics Spa has
19 employees.
View email and phone details for 19
employees at Quince Therapeutics Spa.
Quince Therapeutics Spa's industry is
Biotechnology Research
Quince Therapeutics Spa's top competitors are
Nanomug,
Genenta Science (Nasdaq: Gnta),
Rigenerand Srl,
Eubiome,
Sintetica,
Xgen Venture,
Resalis Therapeutics,
Quince Therapeutics,
Altheia Science,
Sibylla Biotech.
Quince Therapeutics Spa's categories are Biotechnology Research
Quince Therapeutics Spa's founding year is 2007
